ClinicalTrials.gg
RecruitingNCT07204522Updated Oct 2, 2025

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

An observational study in Febrile Neutropenia, sponsored by Shanxi Bethune Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Shanxi Bethune Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Febrile Neutropenia with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Febrile Neutropenia · China.

Started
2025
with 4 others
Observational
3 of 20
2 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Shanxi Bethune Hospital

Among the 20 studies in Febrile Neutropenia with a site in China, this one is one of 5 that started in 2025, is one of 3 observational ones, and was the 17th registered.

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

Browse Febrile Neutropenia studies →

Open to participants now

8 of the 20 studies in Febrile Neutropenia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Febrile Neutropenia with a site in China, or all of them as a file.
02

Study summary

This single-arm, open-label clinical study evaluates the efficacy and safety of a standardized empirical anti-infective escalation protocol for patients with hematological malignancies complicated by febrile neutropenia. The treatment algorithm follows a sequential strategy: initial carbapenem monotherapy (2 days) → if ineffective, combination with vancomycin/linezolid (3 days) → if no response, escalation to antifungal therapy (7 days). For patients demonstrating persistent or recurrent fever with uncontrolled infection parameters after 12-14 days of prior empirical anti-infective therapy, switching to ceftazidime-avibactam combined with aztreonam is implemented. Therapeutic efficacy is assessed through comprehensive evaluation of clinical manifestations, inflammatory biomarkers, radiographic imaging, and microbiological findings. Comprehensive safety surveillance includes continuous monitoring of adverse events and all-cause mortality throughout the treatment course.

Read the detailed description

This study is a single-arm, open-label, observational clinical investigation focusing on patients with hematological malignancies complicated by febrile neutropenia. It aims to evaluate the overall efficacy and safety of a standardized empirical anti-infective treatment algorithm. The protocol employs a unified step-up therapeutic strategy: initial empirical administration of a carbapenem antibiotic (for 2 days); if ineffective, combination with an anti-Gram-positive agent (e.g., vancomycin or linezolid) (for 3 days); if there is still no response, initiation of antifungal therapy (for 7 days); For patients exhibiting persistent or recurrent fever with uncontrolled infection-related parameters after 12-14 days of prior empirical anti-infective therapy, an empirical multidrug-resistant regimen consisting of ceftazidime-avibactam combined with aztreonam is considered. The treatment duration will be adjusted based on neutrophil recovery and febrile status. The study will assess overall efficacy through a comprehensive evaluation of clinical symptoms and signs, inflammatory biomarkers (e.g., C-reactive protein, procalcitonin), radiographic findings, and microbiological results. Safety monitoring will include continuous surveillance of adverse events (AEs) and all-cause mortality throughout the treatment course.

03

Conditions studied

  • Febrile Neutropenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This single-arm, open-label, observational study will enrol adult patients with haematological malignancies who develop febrile neutropenia and are scheduled to receive empirical ceftazidime-avibactam. Eligible participants are aged 18-75 years with acute leukaemia, severe aplastic anaemia, lymphoma or multiple myeloma, an absolute neutrophil count \< 0.5 × 10⁹/L (or expected to fall below this within 48 h), fever ≥ 38.3 °C, ECOG performance status 0-2, and no contraindications such as drug fever, intracranial haemorrhage, pregnancy, or QTc > 500 ms. The cohort will reflect the real-world haematology ward population at high risk for multidrug-resistant Gram-negative infections.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years.
  • Documented haematological : acute leukaemia, severe aplastic anaemia, lymphoma, or multiple myeloma.
  • Neutropenia: (ANC) \< 0.5 × 10⁹/L, or ANC anticipated to fall below this threshold within 48 h; severe neutropenia defined as ANC \< 0.1 × 10⁹/L.
  • Fever: single oral temperature ≥ 38.3 °C (axillary ≥ 38.0 °C), or oral temperature ≥ 38.0 °C (axillary ≥ 37.7 °C) sustained for > 1 h.
  • performance status (ECOG-PS) 0-2.
  • Planned or current empirical use of ceftazidime-avibactam (CAZ-AVI) for febrile neutropenia.

Exclusion criteria

Exclusion Criteria:

  • Drug-related fever or fever attributable to rheumatic/ disease.
  • Concomitant intracranial haemorrhage.
  • Pregnancy, lactation, or intention to become pregnant.
  • Psychiatric disorder or any condition precluding protocol compliance.
  • Life-threatening arrhythmia or > 500 ms on electrocardiography.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Interventions

  • DrugCarbapenems

    First-line empirical agent for febrile neutropenia complicating hematologic malignancies: carbapenem.

  • DrugAnti-Gram-positive agent

    Escalation to a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) is instituted if no defervescence occurs after 48h of first-line therapy; this combination is maintained for 3 days before further escalation in febrile-neutropenia patients with underlying hematologic malignancies.

  • DrugAntifungal agent

    If combination therapy with a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) remains ineffective after 72 h, empirical antifungal coverage is added while continuing antibacterial therapy for an additional 7 days; failure to defervesce thereafter mandates further therapeutic escalation in febrile-neutropenic patients with hematologic malignancies.

  • DrugCeftazidime-avibactam + Aztreonam

    Drug page: AztreonamStudies of AztreonamAztreonam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If the combination of a carbapenem and an anti-Gram-positive agent (vancomycin or linezolid) fails to achieve defervescence after 3 days of treatment, an antifungal agent is added while continuing the original antibacterial regimen for an additional 7 days. Should fever persist or recur with uncontrolled infection-related parameters after 12-14 days of empirical anti-infective therapy, the carbapenem/anti-Gram-positive combination is discontinued. Therapy is then switched to ceftazidime-avibactam plus aztreonam to cover multidrug-resistant pathogens, while concurrently maintaining antifungal treatment. This escalation strategy is indicated for febrile neutropenic patients with underlying hematologic malignancies.

06

What researchers measure

Primary outcomes

  1. Symptom Resolution Rate by Patient-Reported Temperature Diary

    Proportion of patients achieving defervescence (oral temperature \< 38 °C sustained for ≥ 8 h) AND absence of infection-related symptoms recorded in a validated patient diary within 48 h after starting empirical therapy.

    Time frame: two days

  2. C-Reactive Protein Serum Concentration Change (mg/L)

    Absolute decrease from baseline in high-sensitivity CRP measured by immunoturbidimetric assay at 48 h.

    Time frame: two days

  3. Procalcitonin Plasma Concentration Change (ng/mL)

    Absolute decrease from baseline in PCT measured by electrochemiluminescence immunoassay at 48 h.

    Time frame: Two days

  4. Pulmonary Infiltrate Resolution on CT or Chest X-ray

    Proportion of patients with ≥ 50 % reduction in the longest diameter of any lung infiltrate compared with baseline scan.

    Time frame: Two weeks

  5. Pathogen Positivity Rate in Blood or Sterile-Site Cultures

    Cumulative proportion of patients with clinically relevant bacteria or fungi isolated from blood or other normally sterile sites processed by automated BACTEC™ culture system.

    Time frame: one week

  6. Physical Sign Resolution Score by Clinician Examination

    Proportion of patients in whom predefined signs (erythema, tenderness, exudate, etc.) disappear or improve by ≥ 50 % on a 4-point clinician-graded scale.

    Time frame: two days

Secondary outcomes

  1. First-Line Carbapenem Clinical Success Rate

    Proportion achieving defervescence AND ≥ 50 % CRP decrease at 72 h on carbapenem monotherapy.

    Time frame: three days

  2. Carbapenem Plus Anti-Gram-Positive Agent Clinical Success Rate

    Proportion achieving defervescence AND ≥ 50 % CRP decrease at 72 h after adding vancomycin or linezolid.

    Time frame: three days

  3. Antifungal Therapy Biomarker Response Rate

    Proportion with ≥ 50 % reduction in serum galactomannan (Platelia™ ELISA) or β-D-glucan (Fungitell™) at 72 h post-antifungal initiation.

    Time frame: three days

  4. CRE/MDR-GNB Eradication Rate After CAZ-AVI Plus Aztreonam

    Proportion of patients with documented CRE/MDR-GNB whose follow-up blood or sterile-site culture becomes negative within 72 h of starting ceftazidime-avibactam plus aztreonam.

    Time frame: three days

  5. Incidence of Adverse Events Assessed by CTCAE v5.0 (Entire Course)

    Number and grade of drug-related cardiac, hepatic, renal, or allergic adverse events captured through CTCAE v5.0 forms.

    Time frame: From first antimicrobial dose to 30 days post-therapy

  6. All-Cause Mortality Rate

    Proportion of participants who die from any cause within 30 days after enrolment.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

Of 21 observational studies under Febrile Neutropenia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Oct 2, 2025
StartEst.
Sep 22, 2025
Primary completionEst.
Sep 22, 2027
CompletionEst.
Sep 22, 2027
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07204522
Lead sponsor
Shanxi Bethune Hospital
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Sep 22, 2025 (estimated)
Primary completion
Sep 22, 2027 (estimated)
Completion
Sep 22, 2027 (estimated)
Last update
Oct 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion